Axcella Health (NASDAQ:AXLA) and BioCardia (OTCMKTS:BCDA) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, profitability, institutional ownership, earnings, risk and analyst recommendations.
Institutional & Insider Ownership
1.0% of BioCardia shares are owned by institutional investors. 26.0% of BioCardia shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
This is a summary of recent recommendations and price targets for Axcella Health and BioCardia, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Axcella Health currently has a consensus target price of $22.00, suggesting a potential upside of 186.46%. Given Axcella Health’s higher possible upside, equities research analysts clearly believe Axcella Health is more favorable than BioCardia.
This table compares Axcella Health and BioCardia’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Valuation and Earnings
This table compares Axcella Health and BioCardia’s top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Axcella Health||N/A||N/A||-$36.07 million||N/A||N/A|
BioCardia has higher revenue and earnings than Axcella Health.
Axcella Health beats BioCardia on 5 of the 9 factors compared between the two stocks.
Axcella Health Company Profile
There is no company description available for Axcella Health Inc.
BioCardia Company Profile
BioCardia, Inc., a clinical-stage regenerative medicine company, develops therapeutics for cardiovascular diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia. The company is also developing CardiALLO Cell Therapy System, an investigational culture expanded bone marrow derived from mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic systolic heart failure. In addition, it offers the Helix biotherapeutic delivery system; and Morph vascular access product line, which provides catheter products. BioCardia, Inc. is based in San Carlos, California.
Receive News & Ratings for Axcella Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axcella Health and related companies with MarketBeat.com's FREE daily email newsletter.